RARE Ultragenyx Pharmaceutical Inc.

NEUTRAL Impact: 2/10 Insider Cluster (2 insiders)
Horizon days Filed Jun 15, 2026 Processed 5d 9h ago
Insider cluster: 2 insiders, $97K total
Latest settled — T+1d
RARE ▲ +8.29% at T+1d
NEUTRAL call ✓ call won +8.29% · α vs SPY +9.54% · entry $24.85 → $26.91
Next anchor: T+5d in 2d
Last close $27.44 (close Jun 18) · +10.42% from $24.85 entry
Entry anchored
Jun 15, 03:59 PM ET
via Databento tick
T+1d
+8.29%
call +8.29% · α +9.54%
$26.91
settled 5d ago
T+5d
call — · α —
in 2d
T+20d
call — · α —
in 23d
T+60d
call — · α —
in 3mo

Price Chart

Loading chart...

Executive Summary

Two insiders at Ultragenyx sold a combined $97K in open-market transactions on June 15, 2026. The EVP/Chief Legal Officer and a Director each sold modest amounts, representing ~0.004% of the company's $2.4B market cap. The sales are trivial in size and likely routine portfolio adjustments, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$96.9K
Insiders
2

Actionable Insight

The cluster is too small to warrant a trade signal. Monitor for any material insider buying or a larger sell cluster (>0.5% of market cap) that would indicate a change in sentiment. The company's next catalyst is likely pipeline updates or earnings — no immediate read-through from these sales.

Key Facts

  • Two insiders sold shares on June 15, 2026: EVP/Chief Legal Officer sold 1,899 shares ($47K) and a Director sold 2,000 shares ($50K).
  • Total open-market sales of $97K represent ~0.004% of RARE's $2.4B market cap.
  • No C-suite executives (CEO, CFO, COO) participated in the cluster.
  • Recent 30-day insider activity shows 4 prior sells totaling $352K, consistent with routine liquidity-driven selling.

Financial Impact

Total insider sales of $97K, immaterial relative to $2.4B market cap.

insider ownership

Risk Factors

  • Insider sales could accelerate if management anticipates negative clinical or regulatory news.
  • The company's high institutional ownership (88% bullish consensus) may mask insider bearishness if sales grow in size.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (25 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RARE-1781563885174
7 reports for RARE
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+20▲ +16.16%Mar 2, 2026
Filters
Rows
Reports for RARE — sortable, filterable
Type Now
Jun 15, 2026
5d ago
Insider Cluster
NEUTRAL ★ 2/10
$24.85 $26.91▲ +8.29%▲ +9.54%$27.44 (+10.42%)
Jun 11, 2026
9d ago
Institutional Cluster
NEUTRAL ★ 4/10
$23.98 $24.35▲ +1.54%▲ +1.00%$27.44 (+14.43%)
May 5, 2026
6w ago
Press Release
BEARISH ★ 6/10
$25.93 $25.93· 0.00%▼ −0.33%$27.44 (−5.82%)
May 1, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.77 $24.81▲ +0.16%▲ +0.50%$27.44 (+10.78%)
Apr 2, 2026
11w ago
8-K
BULLISH ★ 8/10
$22.45 $22.87▲ +1.87%▲ +1.40%$27.44 (+22.23%)
Mar 27, 2026
12w ago
DEFA14A
NEUTRAL ★ 2/10
$19.30 $20.95▲ +8.55%▲ +5.66%$27.44 (+42.18%)
Mar 2, 2026
15w ago
Insider Cluster
BEARISH ★ 5/10
$23.02 $22.07▲ +4.13%▲ +3.21%$27.44 (−19.20%)
Showing 7 of 7

US Market Status

Market Closed — Opens Mon (29h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access